5 Healthcare Stocks Carrying Upside Price Momentum

Following is information on 5 stocks that have passed our momentum screen today.  Criteria for this screen are:

  • The company trades on a US exchange.
  • The company’s market capitalization is at least $1 billion.
  • The company’s stock has increased at least 5% month-to-date
  • The company operates in the Healthcare sector

The screen returned only five companies.  Their information appears below:

  • Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA): This company operates in the Healthcare sector. Its market capitalization is $1,484,932,000. Its revenue for the most recent fiscal year was $178,980,000, its revenue change year over year was 2055.87%, and its trailing P/E (including extraordinary items) is 17.42. The stock last traded at $11.25, and its price has increased 29.61% month to date. About the company: ARIAD Pharmaceuticals, Inc. discovers, develops, and commercializes small-molecule drugs to treat aggressive cancers. The Company’s first product candidate is an investigational mTOR inhibitor. ARIAD’s second product candidate is an investigational pan BCR-ABL inhibitor for treatment of blood cancers.
  • Biogen Idec Inc. (NASDAQ:BIIB): This company operates in the Healthcare sector. Its market capitalization is $26,190,510,000. Its revenue for the most recent fiscal year was $4,716,423,000, its revenue change year over year was 7.75%, and its trailing P/E (including extraordinary items) is 24.89. The stock last traded at $108.39, and its price has increased 14.42% month to date. About the company:  Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company’s products addresses diseases such as multiple sclerosis, non-Hodgkin’s lymphoma, rheumatoid arthritis, crohn’s disease, and psoriasis.
  • Forest Laboratories, Inc. (NYSE:FRX): This company operates in the Healthcare sector. Its market capitalization is $11,363,520,000. Its revenue for the most recent fiscal year was $4,419,700,000, its revenue change year over year was 5.41%, and its trailing P/E (including extraordinary items) is 11.05. The stock last traded at $39.71, and its price has increased 10.24% month to date. About the company:  Forest Laboratories, Inc. develops, manufactures, and sells both branded and generic forms of ethical products which require a physician’s prescription. The Company also manufactures non-prescription pharmaceutical products sold over-the-counter, which are used for the treatment of a wide range of illnesses. Forest’s products are marketed in the United States and eastern Europe.
  • Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ): This company operates in the Healthcare sector. Its market capitalization is $1,311,071,000. Its revenue for the most recent fiscal year was $173,781,000, its revenue change year over year was 35.29%, and its trailing P/E (including extraordinary items) is 27.31. The stock last traded at $32.18, and its price has increased 9.87% month to date. About the company:  Jazz Pharmaceuticals, Inc. develops and markets treatments for neurological and psychiatric conditions. The Company produces treatments for cataplexy, excessive daytime sleepiness, and ethylene glycol and methanol poisoning in humans.
  • Watson Pharmaceuticals, Inc. (NYSE:WPI): This company operates in the Healthcare sector. Its market capitalization is $8,625,896,000. Its revenue for the most recent fiscal year was $3,566,900,000, its revenue change year over year was 27.71%, and its trailing P/E (including extraordinary items) is 53.17. The stock last traded at $68.20, and its price has increased 5.98% month to date. About the company:  Watson Pharmaceuticals, Inc. develops, manufactures, and sells generic and brand name pharmaceutical products. The Company’s core focus is specialty products, nephrology, urology, and generic products.

(Note: Selected financial data are sourced from screener.co.  All data are assumed to be accurate.)

Invest in Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter >>

More from The Cheat Sheet